[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].

• DOI: 10.3785/j.issn.1008-9292.2020.03.03
• Publication Date: 2020-05-25
• Authors: Jun Chen; Danping Liu; Li Liu; Ping Liu; Qingnian Xu; Lu Xia; Yun Ling; Dan Huang; Shuli Song; Dandan Zhang; Zhiping Qian; Tao Li; Yinzhong Shen; Hongzhou Lu
• Keywords: Hydroxychloroquine; Clinical endpoint

To evaluate the efficacy and safety of hydroxychloroquine (HCQ) in treatment patients with moderate coronavirus disease 2019 (COVID-19).We prospectively enrolled 30 treatment-naïve confirmed COVID-19 after informed consent at Shanghai Public Health Clinical Center. The were randomized 1：1 to HCQ group control group. Patients given 400 mg per day for 5 days plus conventional treatments, while those only. primary endpoint was negative conversion rate SARS-CoV-2 nucleic acid respiratory pharyngeal swab on 7 randomization. This study has been approved by Ethics Committee Center registered online (NCT04261517).One patient developed severe during treatment. On 7, throat swabs 13 (86.7%) cases 14 (93.3%) (P>0.05). median duration from hospitalization virus conservation 4 (1,9) group, which is comparable that [2 (1,4) days, Z=1.27, P>0.05]. time body temperature normalization 1 (0,2) hospitalization, also [1 (0,3) day]. Radiological progression shown CT images (33.3%) (46.7%) all showed improvement follow-up examinations. Four (26.7%) 3 (20%) had transient diarrhea abnormal liver function (P>0.05).The prognosis good. Larger sample size are needed investigate effects COVID-19. Subsequent research should determine better fully consider feasibility experiments such as size.